30
Participants
Start Date
May 31, 2014
Primary Completion Date
January 23, 2019
Study Completion Date
June 30, 2019
Rituximab
Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later
INCB7839
INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
University of Minnesota Medical Center, Fairview, Minneapolis
Masonic Cancer Center, University of Minnesota
OTHER